# A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

> **NCT04482270** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Volunteers

## Interventions

- **DRUG:** fezolinetant

## Key facts

- **NCT ID:** NCT04482270
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-02
- **Primary completion:** 2021-03-22
- **Final completion:** 2021-03-22
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04482270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04482270, "A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04482270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*